Kilitch Drugs (India) Limited has informed the Exchange about Copy of Newspaper Publication
KILITCH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kilitch Drugs published its Q4 and full year financial results (ended March 31, 2026) in newspapers. Consolidated total income grew to Rs 235.47 crore for FY26 from Rs 198.32 crore in FY25, an 18.7% increase. Q4 consolidated revenue was Rs 89.60 crore versus Rs 61.23 crore in Q4 FY25, showing strong sequential and year-over-year growth. Net profit after tax for Q4 stood at Rs 1.49 crore (Q4 FY25: Rs 1.02 crore), while full year PAT was Rs 29.50 crore compared to Rs 24.94 crore, up 18.3%. The board meeting to approve these results was held on May 15, 2026, and the results were published on May 17, 2026.
Strong revenue and profit growth for FY26 reflects healthy operational performance. The stock may see positive sentiment given the double-digit growth in both quarterly and annual numbers.